Last edition
News about "Eisai "
Eisai completes FDA submission for weekly subcutaneous LEQEMBI autoinjector
Eisai has completed the rolling submission of its Supplemental Biologics License Application (sBLA) to the US Food and Drug Administration for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector formulation of lecanemab-irmb (LEQEMBI), following the FDA’s Fast Track designation.
Eisai | 27/11/2025 | By Darshana
Health Canada Grants Authorisation for Leqembi (Lecanemab)
BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.
Eisai | 28/10/2025 | By Dineshwori | 119
Eisai Signs Deal to Develop Tasurgratinib in Greater China Region with SciClone
Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.
Eisai | 01/03/2025 | By Aishwarya | 245
Leqembi sBLA for Alzheimers IV Maintenance Moves Forward with FDA
Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb intravenous (IV) maintenance dosing to the US Food and Drug Administration (FDA).
Eisai | 01/04/2024 | By Manvi | 590
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy